Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Hair Loss Biopharma Firm Veradermics Raises $256 Million in IPO
04.02.2026 03:19
At the IPO price, Veradermics has a market value of about $596 million based on the outstanding shares listed in its filings. Wellington Management had indicated interest in purchasing as much as $30 million in shares at the IPO price, according to the filings.
Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
04.02.2026 00:58
While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting-edge healthcare segment.
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
04.02.2026 00:09
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
The Smartest Growth Stock to Buy With $30 Right Now
04.02.2026 00:08
This pre-revenue biopharmaceutical stock is a home run swing worth taking.
Novo Nordisk shares plunge amid lower 2026 sales outlook
03.02.2026 17:49
Investing.com - Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply midday Tuesday after the Wegovy-maker posted fourth-quarter results and issued a sales warning for 2026.
Eli Lilly Stock Falls Ahead of Earnings -- Phase 3 Trials Could Fuel Next Wave of Growth
03.02.2026 17:27
LLY Earnings Preview: Medicare Access and New Launches Could Boost Revenue in 2026
Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge
03.02.2026 17:15
Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu
Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight
03.02.2026 17:05
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
Novo warns sales to tumble on tougher competition in US
03.02.2026 17:02
The Danish drugmaker’s annual sales last fell in 2017 amid a price war over insulin in the US. Analysts had anticipated a conservative forecast and a decline in sales, but the magnitude of the potential drop is larger than had been predicted.
Pfizer Stock Drops On Obesity-Drug Study Data
03.02.2026 15:32
Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war last year. The company said the injected drug, PF’3944, helped people lose 12.3% of their body weight versus a placebo after 28 weeks of treatment in a mid-stage clinical trial. Analysts said the drug’s efficacy was slightly inferior to Eli Lilly’s Zepbound weight-loss drug, and raised concerns about study subjects discontinuing treatment due to side effects.
Eli Lilly Expands Weight Loss And Pipeline Bets As Valuation Draws Focus
03.02.2026 15:09
Eli Lilly (NYSE:LLY) is committing $3.5b to a new Pennsylvania manufacturing facility for next generation injectable weight loss therapies. The company has entered a gene editing collaboration with Seamless Therapeutics targeting certain forms of hearing loss. Lilly also announced a partnership with Repertoire Immune Medicines focused on autoimmune disease therapies. Eli Lilly comes into these moves with its share price at $1,044.13 and a 1 year return of 29.8%. Over 3 years, the stock is...
Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight.
03.02.2026 14:59
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?
03.02.2026 14:39
Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.
NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer
03.02.2026 13:55
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Revvity: Close To A Buy, Not Quite There
03.02.2026 13:35
Revvity, Inc. is rated a Hold due to stretched valuation, ongoing weakness in China diagnostics and NIH funding. Read more on RVTY stock here.
Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly
03.02.2026 13:00
ZHUZHOU, China, February 03, 2026--Zonsen PepLib Biotech Inc. ("PepLib") today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company ("Lilly"). Under the agreement, both parties will jointly advance the development of novel peptide-based drug candidates leveraging PepLib’s robust and diverse proprietary peptide libraries and discovery technology platforms.
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
03.02.2026 12:40
Merck (MRK) delivered earnings and revenue surprises of +0.62% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Pfizer dips on new data for obesity drug acquired in $10B deal
03.02.2026 12:01
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Novo Nordisk shares tumble after company forecasts sales declines this year
03.02.2026 11:57
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
Eli Lilly and Company (LLY) to Invest Over $3.5 Billion in New Manufacturing Facility in Pennsylvania
03.02.2026 09:34
Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device […]